Lifecore Biomedical Earnings Call Signals Profitable Shift

Lifecore Biomedical, Inc. ((LFCR)) has held its Q5 earnings call. Read on for the main highlights of the call.

Lifecore Biomedical’s latest earnings call struck an optimistic tone as management highlighted robust revenue growth, a sharp swing to positive adjusted EBITDA, and meaningful cost cuts. Executives acknowledged ongoing GAAP losses and margin gaps versus midterm targets, but emphasized operational progress, growing customer validation, and a strengthening late-stage pipeline as reasons for cautious confidence.

Strong Revenue Growth

Lifecore reported third-quarter revenue of $31.1 million, up 26% from $24.7 million a year earlier, underscoring solid momentum in its core businesses. The gain was led by a $4.8 million jump in hyaluronic acid manufacturing and a $1.6 million increase in CDMO revenue, with higher product volumes partly offset by lower development revenue.

Adjusted EBITDA Turnaround

Profitability on an adjusted basis improved dramatically, with adjusted EBITDA rising to $3.1 million from a loss of $1.8 million in the prior-year quarter. Management attributed the $4.9 million swing to stronger gross profit and disciplined expense control, framing the result as an important proof point on the path to higher long-term margins.

Gross Profit Improvement

Gross profit increased to $7.8 million from $5.4 million, driven mainly by better performance in the HA manufacturing segment. A $4.3 million rise in HA gross profit reflected higher production volumes and better absorption of fixed manufacturing costs, partially offsetting pressure in the CDMO business.

Material SG&A Reductions

Selling, general and administrative expenses fell to $8.9 million from $14.8 million, a roughly 40% reduction that materially boosted earnings quality. The decline included $2.2 million less in recurring accounting, legal and consulting costs and $3.7 million in lower nonrecurring legacy expenses, signaling that past overhangs are easing.

Quality and Regulatory Validation

Management highlighted a successful FDA inspection earlier in the year alongside five positive customer audits during the quarter, including due diligence by a large multinational. These outcomes were presented as strong external validation of Lifecore’s quality systems and as key drivers of rising customer confidence in its CDMO platform.

Business Development and New Wins

Commercial momentum accelerated, with two new customers signed in the quarter and two more added after quarter-end, among them a late-stage GLP-1 program. One of the post-quarter wins is a commercial site transfer from a large multinational that management believes could rank among the company’s largest customers once fully commercialized.

Late-Stage Pipeline and Commercialization Progress

The company now counts 11 late-stage programs with potential launches spread between 2026 and 2029, building a visible pipeline of future revenue. Operationally, Lifecore installed and qualified new automated manufacturing equipment, completed two Phase III clinical batches, and plans validation batches in early 2026 for a major pharmaceutical client.

Operational Productivity Gains

Over the past 18 months Lifecore has reduced its manufacturing workforce by more than 20% while maintaining similar output, pointing to meaningful productivity gains. Looking ahead, management plans to implement a new ERP system in the first quarter of 2026 and has hired a Head of Business Transformation to unlock further efficiency and procurement savings.

Reaffirmed Transition-Period Guidance

For the roughly seven-month transition period ending Dec. 31, 2025, management reaffirmed revenue guidance of $74 million to $76 million, with adjusted EBITDA of $12 million to $14 million and a net loss of $18.4 million to $16.4 million. Based on year-to-date performance, this implies fourth-quarter revenue of $34 million to $36 million and adjusted EBITDA of $7 million to $9 million, or about a 17% margin at the midpoint.

Continued Net Loss

Despite the improved operational picture, Lifecore remained unprofitable on a GAAP basis, posting a net loss of $10.0 million, or $0.29 per diluted share, versus a $16.2 million loss, or $0.53, a year earlier. Management stressed that narrowing losses reflect structural cost reductions and scaling benefits, but acknowledged that consistent profitability remains a key milestone ahead.

CDMO Gross Profit Decline and Product-Mix Pressure

Within the CDMO segment, gross profit declined by $1.9 million as lower development revenue and adverse product mix weighed on results. Management cited about $1.4 million less in development work and lower aseptic gross profit as headwinds, only partly offset by favorable manufacturing absorption and higher volumes in other areas.

Timing and Concentration Risk

Executives flagged timing risk as a major consideration, noting that a significant growth inflection is expected in 2027 with the company’s largest customer. In addition, commercial site transfers, including a notable new win from a multinational, are expected to take roughly 24 to 30 months to fully complete, exposing results to execution and schedule uncertainties.

Unfavorable Debt Derivative and Legacy Impacts

The quarter included a small unfavorable adjustment related to debt derivatives, and management acknowledged some lingering impacts from legacy items. While these expenses have declined sharply versus prior periods, they still create a modest financial overhang that investors will watch as the balance sheet continues to normalize.

Margins Still Below Midterm Target

Lifecore reiterated a midterm goal of reaching a 25% adjusted EBITDA margin, but the current trajectory remains short of that level, with the quarter’s margin around 10%. The implied 17% margin for the transition period suggests progress, and management is banking on higher volumes, procurement savings and ERP-driven efficiencies to close the gap over time.

Development Revenue Volatility

Management also cautioned that development revenue can be lumpy from quarter to quarter as individual projects ramp and roll off, contributing to volatility in CDMO metrics. A completed discrete project weighed on year-over-year comparisons this quarter, and investors were reminded to focus more on multi-year trends than single-period swings.

Forward-Looking Guidance and Outlook

Beyond reaffirmed transition-period targets, Lifecore signaled that calendar 2026 revenue is likely to be slightly back-half weighted, with about 45% in the first half and 55% in the second. Management continues to frame 2025 and 2026 as foundation-building years aimed at scaling late-stage programs, driving margin expansion and positioning the business for a larger revenue step-up later in the decade.

Lifecore’s earnings call painted a picture of a CDMO platform steadily gaining scale, credibility and operational discipline, even as GAAP profitability remains out of reach for now. For investors, the story hinges on execution: converting late-stage programs and major site transfers into sustained high-margin revenue while managing timing, customer concentration and margin pressures along the way.